EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, COYA: Coya Therapeutics Inc

24 Oct 25 15:59
LAST:

6.330

CHANGE:
 0.68		OPEN:
6.600		HIGH:
6.810		ASK:
0.000		VOLUME:
1.11M
CHG(%):
9.74		PREV:
6.980		LOW:
6.070		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 256.6006.8106.0706.3001.12M
23 Oct 257.4007.5006.9106.980478.5K
22 Oct 256.7507.5506.7307.360844.4K
21 Oct 256.6846.6846.1906.47076.4K
20 Oct 256.4306.5606.1206.410150.6K
17 Oct 256.2836.4356.0626.36072.3K
16 Oct 256.7206.9706.1806.300119.7K
15 Oct 257.1707.1706.5406.710209.3K
14 Oct 255.9207.7505.8307.2001.44M
13 Oct 256.1706.1705.9406.06032.2K

COMPANY PROFILE

Name:Coya Therapeutics Inc
About:Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Sector:Healthcare
Industry:Biotechnology
Address:5850 San Felipe St., Houston, TX, United States, 77057
Website:https://coyatherapeutics.com
CIK:0001835022
ISIN:US22407B1089
FIGI:BBG00Z4HBCB9

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:6.705.9%
MA10:6.624.5%
MA20:6.340.2%
MA50:6.202.2%
MA100:6.074.3%
MA200:6.103.8%
STO14:14.20 
RSI14:47.83
WPR14:-81.54 
MTM14:-0.09
ROC14:-0.01 
ATR:0.63 
Week High:7.5519.3%
Week Low:6.064.4%
Month High:7.7522.4%
Month Low:5.103.8%
Year High:10.2461.8%
Year Low:4.6536.1%
Volatility:6.15